Member Info for Porter_

Imaging trading for a 10% profit and this bags and rerates again :)
Buys rolling in, traders risk getting locked out!

Tintra PLC Contracts with Temenos AG (09/14/2022)

Tintra PLC announced that it has contracted with Temenos AG (Temenos). Temenos will provide its core banking software to Tintra, which will be integrated with Tintra's innovative artificial intelligence-based approach to customer and transaction identification. The integration of the Temenos core banking software is a fundamental element in enabling the roll out of the Company's strategy, as set out in the recently published annual report.

Temenos Launches Self-Service Financial Crime Mitigation on Temenos Banking Cloud (12/10/2022)

GENEVA--(BUSINESS WIRE)--Temenos (SIX: TEMN) today announced that it is the first to market with a SaaS offering that enables banks to manage financial crime mitigation (FCM) with composable banking services on a secure, continually evolving, self-service platform. Temenos’ FCM-as-a-Service delivers pre-built configurations aligned to global industry regulations. Now with self-provisioning and automatic upgrades for fast compliance and time to value, banks can achieve lower total cost of owners.

https://www.youtube.com/watch?v=Ne1e40aRE44

No, they said they’ve been advised still not to buy shares owing to the risk of being accused of insider trading. Seems we should still expect more market responsive company updates to follow, based on their comments.

I’m holding tight. Expecting TR1 updates to follow from the majors. Would be silly to sell at such a low price.
$165m license contract / a float of 175m shares is surely a market valuation of 94 Cents or 85p a share alone!

Looking forward to when the Americans see the presentation updates. The share flew when they were able to trade.

£18k buy just showed up. Nice to see others see the prospects!

They said that the presentation will be shortly available for playback from the presentation website. Deffo worth a watch.

Really impressed with the presentation. The board clearly have an excellent background and are realistic on goals and milestones, not ramping with false promises and expectations like some management in other PLC’s.

Good to know that major investors such as AXA have been involved since 2015, so says to me that the company is a very secure investment despite all the troubles in the world.

Also highly reassured by the comments on the Directors not being able to buy shares currently to prevent accusations of insider trading owing to their recent contract awards. Plus, they aren’t issuing confetti shares and are passionate about their science, not shareholder funds, so prospects of share dilution unless a major comes in are slim, which is a breath of fresh air!

Agree, swooping for stop losses perhaps?

The trades aren’t all reporting correctly owing to the margins and volatility, so the SP isn’t rightly reflected. Just means investors get a bargain entry price IMO :)

$160.5m license award

Summary from Mondays RNS for new investors:

“Milestone payments up to commercial launch are $26.5m, including $5m on grant of IND by the FDA (anticipated in late 2023). Total milestones of $160.5m are payable to the Company in relation to the first neurodevelopmental disorder indication under the license. Royalties payable to Evgen on sales are in the low to medium double-digit range in all scenarios, including on-licensing by Stalicla and use of SFX-01 in further licensed indications.”

I bought two tranches of shares yesterday, both buys showed up as sales.
Same happening today and many of those sells are clearly buys.
When will the MM’s get a system that accurately reports trades?
Expecting a big day, providing the systems fix their technical issues.

Proactive Investors:

Evgen Pharma PLC (AIM:EVG) said changes to its glioblastoma programme are expected to extend its cash runway by more than a year.

It said it will pull the trigger on the trial of its lead asset, SFX-01, in healthy volunteers to assess its pharmacokinetic its pharmacodynamic properties.

Specifically, it wants to see how the new coating for the pill performs. Top-line data are expected in the first half of next year.

It has also taken the decision to embark on an investigator-sponsored clinical study (ISS) to assess the drug’s potential in glioblastoma, a form of brain cancer while carrying out further pre-clinical work.

Evgen said it had been advised to take this route by experts in the field, and added the approach would allow it to ‘de-risk’ a subsequent phase II trial.

It will allow researchers to assess with ‘more clarity’ how the active ingredient, sulforaphane. enters the tumour and interacts with it at a molecular level.

Carrying out the ISS will be Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre, in the Netherlands, who is at the forefront of glioblastoma research.

The company said it would look for partnering opportunities while the ISS was being undertaken.

The impact of this change of tack is to push out the cash runway to at least the end of the fourth quarter of 2024 rather than the third quarter of next year. This will extend into 2025 if a deal inked with Swiss drug developer Stalicla earlier this week generates the envisaged milestone payments.

“We continue to explore partnering opportunities in the context of a considerably longer cash runway, with the prospect of significant further non-dilutive cash inflows from our partners," said Evgen chief executive Dr Huw Jones.

Still the possibility of further RNS’s such as majors accumulating more shares, including AXA and Octopus :)

RNS:

“In glioblastoma (GBM), Evgen has been consulting widely with world-renowned experts in the treatment of brain cancers with regards to the planned study.“

The Nederlands are investing a crazy amount of money in medical health atm and most of the big pharma groups have lots of large factories and medical centres there.

A great place to base their studies, with a strategic step in taking the company global.

£1.3M of shares traded today. Shows there’s a market both ways. Doubt the likes of AXA will want to lose their holding on the share though and could possibly increase themselves given the award update.

Will be interesting to see the end of day share consolidation and if we have any large trades processed ahead of tomorrows presentation :)

Investor meeting is 1pm tomorrow.
You can register and join on the link towards the bottom of the last RNS.
If I try share it most likely won’t show :)

If you’re still on the fence and not sure if it’s too late to invest as may have missed the train, last week, TRLS another pharma share, held an Investors presentation and the SP flew. Tomorrow is a big day IMO.